FDA accepts Alexion’s application for next-generation PNH drug
Soliris, the drugmaker's cash cow approved for the same disease, faces biosimilar competition as patent expiry looms.
Soliris, the drugmaker's cash cow approved for the same disease, faces biosimilar competition as patent expiry looms.